Sex and Age-Based Differences in Immune Responses to a Peptide Vaccine for Melanoma in Two Clinical Trials

Objectives: Little is known about the impact of patient age and biological sex on immune responses to melanoma vaccines, especially CD4<sup>+</sup> T cell immune responses to peptides presented by Class II MHC molecules. Methods: We assessed the impact of age and sex on CD4+ T cell and a...

Full description

Bibliographic Details
Published in:	Vaccines
Main Authors:	Serena M. Vilasi, Craig L. Slingluff
Format:	Article
Language:	English
Published:	MDPI AG 2025-02-01
Subjects:	melanoma vaccine peptide vaccine T cell response patient sex patient age
Online Access:	https://www.mdpi.com/2076-393X/13/2/194

Similar Items

Nanoliposomal VEGF-R2 peptide vaccine acts as an effective therapeutic vaccine in a murine B16F10 model of melanoma
by: Fatemeh Zahedipour, et al.
Published: (2023-06-01)

Peptide Vaccines in Melanoma: Chemical Approaches towards Improved Immunotherapeutic Efficacy
by: Beáta Biri-Kovács, et al.
Published: (2023-01-01)

Local Enrichment with Convergence of Enriched T-Cell Clones Are Hallmarks of Effective Peptide Vaccination against B16 Melanoma
by: Anna Vyacheslavovna Izosimova, et al.
Published: (2024-03-01)

Nanoliposome-encapsulated MAGE peptides: A promising melanoma vaccine to activate human dendritic cells
by: Azin Bavafa, et al.
Published: (2025-05-01)

IMMUNOTHERAPY FOR MELANOMA
by: E. A. Borobova, et al.
Published: (2017-09-01)

Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma
by: Robert O Dillman, et al.
Published: (2019-06-01)

B16 melanoma control by anti-PD-L1 requires CD8+ T cells and NK cells: application of anti-PD-L1 Abs and Trp2 peptide vaccines
by: Sunhee Ji, et al.
Published: (2021-07-01)

Melanoma Vaccines: Comparing Novel Adjuvant Treatments in High-Risk Patients
by: Joseph C. Broderick, et al.
Published: (2025-06-01)

Survival Decreases With Aging in Turkish Cutaneous Melanoma Patients
by: Faruk Tas, et al.
Published: (2025-04-01)

A Bibliometric Analysis of Melanoma Treated with Vaccinations Research from 2013 to 2023: A Comprehensive Review of the Literature
by: Xinyu Wang, et al.
Published: (2023-06-01)

Independent association of sex, age and the melanoma subtype with histological regression in invasive melanomas: A retrospective study
by: Clio Dessinioti, et al.
Published: (2024-12-01)

Melanoma vaccines and modulation of the immune system in the clinical setting: building from new realities
by: Florencia Paula Madorsky Rowdo, et al.
Published: (2012-05-01)

Association between dermoscopic features and tumor thickness, diameter, age, and sex in acral melanoma: A cross-sectional studyCapsule Summary
by: Yaei Togawa, MD, PhD, et al.
Published: (2025-10-01)

Immunization coverage and timeliness of vaccination in young patients with inborn errors of metabolism: a French multicentric study
by: Anne-Sophie Renous, et al.
Published: (2025-03-01)

Sex-disaggregated outcomes of adverse events after COVID-19 vaccination: A Dutch cohort study and review of the literature
by: Janneke W. Duijster, et al.
Published: (2023-01-01)

The effect of sex on responses to influenza vaccines
by: Lucy Denly
Published: (2021-05-01)

Peptide Vaccine: Progress and Challenges
by: Weidang Li, et al.
Published: (2014-07-01)

Antitumor effect of oral cancer vaccine with Bifidobacterium delivering WT1 protein to gut immune system is superior to WT1 peptide vaccine
by: Toshiro Shirakawa, et al.
Published: (2018-01-01)

mRNA melanoma vaccine revolution spurred by the COVID-19 pandemic
by: Ziyang Xu, et al.
Published: (2023-03-01)

Coadministration of seasonal influenza and COVID-19 vaccines: A systematic review of clinical studies
by: Cécile Janssen, et al.
Published: (2022-11-01)

Editorial: Peptides against infectious diseases: from antimicrobial peptides to vaccines
by: Joanna Bojarska, et al.
Published: (2024-12-01)

Studies with herpes zoster vaccines in immune compromised patients
by: Myron J. Levin, et al.
Published: (2017-12-01)

Peptide Dose and/or Structure in Vaccines as a Determinant of T Cell Responses
by: Graham R. Leggatt
Published: (2014-07-01)

Age- and Sex-Graded Data Evaluation of Vaccination Reactions after Initial Injection of the BNT162b2 mRNA Vaccine in a Local Vaccination Center in Germany
by: Manuela A. Hoffmann, et al.
Published: (2021-08-01)

Evolution and Progress of mRNA Vaccines in the Treatment of Melanoma: Future Prospects
by: Dimitrios Bafaloukos, et al.
Published: (2023-03-01)

Cyclophosphamide augments the efficacy of in situ vaccination in a mouse melanoma model
by: Noah Tsarovsky, et al.
Published: (2023-09-01)

Sex-specific difference for melanoma from immunotherapy advancement
by: Qianqian Li, et al.
Published: (2024-11-01)

VACCIMEL, an allogeneic melanoma vaccine, efficiently triggers T cell immune responses against neoantigens and alloantigens, as well as against tumor-associated antigens
by: Ibel Carri, et al.
Published: (2025-01-01)

Matrix metalloproteinases-9 as a promising target for anti-cancer vaccine: inhibition of melanoma tumor growth in mice immunized with syngeneic MMP-9 peptides
by: M. Waheed Roomi, et al.
Published: (2019-11-01)

Sex differences in COVID-19 vaccine confidence in people living with HIV in Canada
by: Jessica Lu, et al.
Published: (2024-12-01)

Intratumoral administration of mRNA COVID-19 vaccine delays melanoma growth in mice
by: Dylan T. Boehm, et al.
Published: (2025-02-01)

Patient satisfaction with pharmacist-administered COVID-19 vaccines in Poland: a survey study in the vaccination centres context
by: Piotr Merks, et al.
Published: (2022-11-01)

Recent developments in peptide vaccines against Glioblastoma, a review and update
by: Reza Salahlou, et al.
Published: (2025-06-01)

Sex and COVID-19 vaccination uptake and intention in the Democratic Republic of Congo, Nigeria, Senegal, and Uganda
by: Rawlance Ndejjo, et al.
Published: (2024-06-01)

Engineered antibody cytokine chimera synergizes with DNA-launched nanoparticle vaccines to potentiate melanoma suppression in vivo
by: Nicholas J. Tursi, et al.
Published: (2023-02-01)

On the Road to Individualization of Vaccination: the Significance of Age and Sex
by: B. V. Karalnik
Published: (2022-01-01)

The immune system contributes to the effectiveness of vaccine therapy in patients with metastatic melanoma
by: I. N. Mikhaylova, et al.
Published: (2023-05-01)

Lymphadenopathy after COVID-19 vaccine mimicking lymph-node progression in a patient with metastatic melanoma
by: Julia Verdaguer Faja, et al.
Published: (2022-10-01)

An update on the relevance of vaccine research for the treatment of metastatic melanoma
by: Robert O Dillman
Published: (2017-12-01)

Enhancement of Tetravalent Immune Responses to Highly Conserved Epitopes of a Dengue Peptide Vaccine Conjugated to Polystyrene Nanoparticles
by: Yanqi Chan, et al.
Published: (2020-07-01)